0624 Samelisant (SUVN-G3031), Baseline Characteristics from a Phase-2 Study Evaluating Efficacy and Safety in Patients with Narcolepsy-V45IS1 0624 Samelisant (SUVN-G3031), Baseline Characteristics from a Phase-2 Study Evaluating Efficacy and Safety in Patients with Narcolepsy-V45IS1 Download Treatment initiation and utilization patterns of pharmacotherapies for early-onset idiopathic restless legs syndrome-V96 0628 Epilepsy Control and Night Sleep Duration and Afternoon Siesta-V45IS1
